Atezolizumab

Drug Profile

Atezolizumab

Alternative Names: MPDL-3280A; RG-7446; RO 5541267; TECENTRIQ

Latest Information Update: 24 Feb 2017

Price : $50

At a glance

  • Originator Genentech; University Medical Center Groningen
  • Developer ARCAGY/GINECO Group; Astex Pharmaceuticals; Chugai Pharmaceutical; Clovis Oncology; Columbia University; Dana-Farber Cancer Institute; European Organisation for Research and Treatment of Cancer; Fondazione Michelangelo; Genentech; Immune Design; Incyte Corporation; M. D. Anderson Cancer Center; Roche; University Medical Center Groningen; University of California at San Francisco; University of California System; Yale University
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD274 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer; Urogenital cancer
  • Preregistration Bladder cancer
  • Phase III Breast cancer; Colorectal cancer; Fallopian tube cancer; Malignant melanoma; Ovarian cancer; Peritoneal cancer; Prostate cancer; Renal cell carcinoma; Small cell lung cancer
  • Phase II Chronic lymphocytic leukaemia; Soft tissue sarcoma; Solid tumours
  • Phase I/II Diffuse large B cell lymphoma; Follicular lymphoma
  • Phase I Acute myeloid leukaemia; Multiple myeloma; Myelodysplastic syndromes
  • No development reported Haematological malignancies

Most Recent Events

  • 18 Feb 2017 Efficacy and adverse event data from the phase II IMmotion150 trial in Renal cell carcinoma presented at the 2017 Genitourinary Cancers Symposium (ASCO-GeCS-2017)
  • 17 Feb 2017 Preregistration for Non-small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in Japan (IV)
  • 01 Feb 2017 Hoffmann-La Roche plans a phase III trial for Ovarian cancer, Fallopian tube cancer, Peritoneal cancer (Late-satge disease) in Australia and USA (NCT03038100)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top